Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

The findings of a novel study on the performance of coronavirus tests in children were presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

A team of researchers from the University of Toronto (Toronto, Canada) set out to investigate the accuracy of coronavirus antigen and antibody tests in a pediatric population. The aim was to overcome the problem of the majority of FDA-authorized coronavirus tests being validated primarily using data from adults, meaning that these tests might not be as accurate in pediatric patients, thus posing a key challenge with COVID-19 care.

The researchers tested 140 asymptomatic children and adolescents (ages 5 to 18) with a coronavirus antigen test and an antibody test. From this, they found that the tests’ performance in pediatric individuals was on par with the tests’ performance in adults. All of the antigen test results were negative, which was in keeping with the fact that all study participants were asymptomatic. Furthermore, all of the study participants (3%) who had positive antibody test results had also previously tested positive for the coronavirus in the past.

“A lot of the literature focuses on adults right now, and our study has been one of the few to go into the community and see the performance of these tests in asymptomatic school children and adolescents,” said Mary Kathryn Bohn, a PhD candidate at the University of Toronto, who led the research. “These types of studies will be really important, especially as the school year starts.”

Related Links:
University of Toronto 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.